Director/PDMR Shareholding

RNS Number : 0556F

Advanced Medical Solutions Grp PLC

18 April 2011

 



For Release: 18 April 2011

Advanced Medical Solutions Group plc

("AMS" or the "Company")

Directors' shareholdings

Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, announces that the Board, following a recommendation from the Remuneration Committee, has granted new share options to the following Directors under the Advanced Medical Solutions Long Term Incentive Plan (the 'LTIP') on 15 April 2011.  The vesting of these options is subject to certain performance criteria over a three year period.

Director	Options prior to grant	Options granted	Resultant holding
Chris Meredith, Chief Executive Officer	589,234	306,818	896,052
Mary Tavener, Group Finance Director	193,408	159,126	352,534

- Ends -

For further information, please visit www.admedsol.com or contact:

Advanced Medical Solutions Group plc	Tel: [phone]
Chris Meredith, Chief Executive Officer Mary Tavener, Group Finance Director
Tavistock Communications	Tel: [phone]
John West / Chris Munden / Andrew Dunn / Lydia Eades
Investec Bank plc	Tel: [phone]
Gary Clarence / Daniel Adams / Patrick Robb

Notes to Editors:

AMS' advanced woundcare products are based on an extensive range of technologies including alginates, silver alginates and hydrophilic polyurethane foams. These and other products pioneer the concept of moist wound healing, allowing wounds to heal faster and with less pain and scarring. They protect the wound, deal with tissue fluids and provide an optimal environment for healing to occur. Silver is widely recognised as a safe and effective broad-spectrum anti-microbial agent for infection control.

AMS' wound closure and sealants products are based on cyanoacrylate adhesive ("superglue") technology developed for medical applications. Tissue adhesives offer significant benefits over conventional ways of closing wounds following trauma or surgical incision. They are simple to use, non-invasive, help to reduce the risk of infection, minimise trauma to the patient and provide good clinical and cosmetic outcomes. The technology is also ideally suited to protecting skin from breakdown or for use as a skin sealant to help prevent infection of surgical sites.

 

END

 

 

RDSBRGDSSGBBGBU